Anna Olsson‐Brown

3.1k total citations
50 papers, 560 citations indexed

About

Anna Olsson‐Brown is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Anna Olsson‐Brown has authored 50 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 10 papers in Immunology and 9 papers in Genetics. Recurrent topics in Anna Olsson‐Brown's work include Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (8 papers) and Virus-based gene therapy research (7 papers). Anna Olsson‐Brown is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (8 papers) and Virus-based gene therapy research (7 papers). Anna Olsson‐Brown collaborates with scholars based in United Kingdom, United States and Australia. Anna Olsson‐Brown's co-authors include Bryan D. Jones, Emma Vaux, Joseph J. Sacco, Munir Pirmohamed, Paul Carroll, Tim Cooksley, Daniel L. Morganstein, Peter Trainer, James Larkin and Paul Lorigan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Anna Olsson‐Brown

43 papers receiving 552 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Olsson‐Brown United Kingdom 13 285 108 99 74 64 50 560
Pamela Mancuso Italy 16 217 0.8× 83 0.8× 40 0.4× 33 0.4× 14 0.2× 63 748
Yi‐Ping Hung Taiwan 17 337 1.2× 193 1.8× 45 0.5× 55 0.7× 18 0.3× 45 839
Laura Vincent United States 15 237 0.8× 48 0.4× 116 1.2× 45 0.6× 75 1.2× 41 840
Colleen Pelser United States 11 337 1.2× 110 1.0× 72 0.7× 33 0.4× 11 0.2× 16 828
Saurabh Nagar United States 16 113 0.4× 133 1.2× 57 0.6× 40 0.5× 32 0.5× 62 775
Tsang-En Wang Taiwan 16 199 0.7× 134 1.2× 91 0.9× 19 0.3× 10 0.2× 53 798
Michael O’Sullivan Australia 14 54 0.2× 212 2.0× 135 1.4× 23 0.3× 27 0.4× 52 676
Sebastian E. Sattui United States 15 80 0.3× 66 0.6× 81 0.8× 32 0.4× 16 0.3× 53 772
Floor Abbink Netherlands 18 243 0.9× 55 0.5× 38 0.4× 12 0.2× 28 0.4× 37 724
Bradley S. Stolshek United States 16 266 0.9× 37 0.3× 142 1.4× 25 0.3× 15 0.2× 44 753

Countries citing papers authored by Anna Olsson‐Brown

Since Specialization
Citations

This map shows the geographic impact of Anna Olsson‐Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Olsson‐Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Olsson‐Brown more than expected).

Fields of papers citing papers by Anna Olsson‐Brown

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Olsson‐Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Olsson‐Brown. The network helps show where Anna Olsson‐Brown may publish in the future.

Co-authorship network of co-authors of Anna Olsson‐Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Olsson‐Brown. A scholar is included among the top collaborators of Anna Olsson‐Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Olsson‐Brown. Anna Olsson‐Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pozas, Javier, James Larkin, Anna Olsson‐Brown, et al.. (2025). Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study. Cancers. 17(15). 2461–2461.
2.
3.
Ibraheim, Hajir, et al.. (2024). The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy. Best Practice & Research Clinical Gastroenterology. 72. 101944–101944. 3 indexed citations
4.
Olsson‐Brown, Anna, et al.. (2024). Immune checkpoint inhibitor-induced cholangitis—a three-case series. SHILAP Revista de lepidopterología. 5(4). 818–825.
5.
Carr, Aisling, Frederick W. Vonberg, Kate Young, et al.. (2024). Neurological complications of immune checkpoint inhibitors: a practical guide. Practical Neurology. 25(2). 116–126. 7 indexed citations
6.
Olsson‐Brown, Anna, et al.. (2024). Enhancing systemic anti-cancer treatment (SACT) capacity: implementing and using subcutaneous atezolizumab. British Journal of Nursing. 33(Sup17). S1–S13.
7.
Olsson‐Brown, Anna, Vincent Yip, Lorenzo Ressel, et al.. (2023). TNF‐α induced extracellular release of keratinocyte high‐mobility group box 1 in Stevens‐Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis. The Journal of Dermatology. 50(9). 1129–1139. 8 indexed citations
8.
Adeniji, Johnson Adekunle, et al.. (2023). 2183P The relevance of HFpEF in immunotherapy-induced myocarditis: An analysis of 65 patients. Annals of Oncology. 34. S1131–S1131. 1 indexed citations
9.
Olsson‐Brown, Anna, Vincent Yip, Lorenzo Ressel, et al.. (2022). TNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis. Journal of Investigative Dermatology. 143(6). 1023–1030.e7. 16 indexed citations
10.
Gent, David, Nasim Ali, Anna Olsson‐Brown, et al.. (2022). Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights. SHILAP Revista de lepidopterología. 15(3). 950–959. 2 indexed citations
11.
Liu, Yan, et al.. (2022). Multidisciplinary supportive care in cancer: cost analysis. BMJ Supportive & Palliative Care. 14(e1). e512–e515. 2 indexed citations
12.
Olsson‐Brown, Anna, Mark Baxter, Laura Feeney, et al.. (2022). The association of pre-existing autoimmune disease and immune-related adverse events secondary to immune checkpoint inhibition therapy in a UK multicenter cohort.. Journal of Clinical Oncology. 40(16_suppl). 2522–2522.
13.
Ye, Weiyu, Anna Olsson‐Brown, Robert Watson, et al.. (2021). Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. British Journal of Cancer. 124(10). 1661–1669. 33 indexed citations
14.
Olsson‐Brown, Anna, Andrew Gibson, Joshua Gardner, et al.. (2021). Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. Toxicological Sciences. 186(1). 58–69. 27 indexed citations
15.
Sasson, Sarah C., Laura Wilkins, Oliver Brain, et al.. (2021). Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma. Scientific Reports. 11(1). 19253–19253. 6 indexed citations
16.
Pickles, Oliver, Lennard Y. W. Lee, Thomas Starkey, et al.. (2020). Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?. British Journal of Cancer. 123(5). 691–693. 12 indexed citations
17.
Middleton, Mark R., Francesca Aroldi, Joseph J. Sacco, et al.. (2020). An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. Journal of Clinical Oncology. 38(15_suppl). e22050–e22050. 16 indexed citations
18.
Middleton, Mark R., Joseph J. Sacco, Jaime R. Merchan, et al.. (2019). Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors. Journal for ImmunoTherapy of Cancer. 7. 1 indexed citations
19.
20.
Jones, Bryan D., Emma Vaux, & Anna Olsson‐Brown. (2019). How to get started in quality improvement. BMJ. 364. k5408–k5408. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pamela Mancuso Breakdown of academic impact, for papers by Yi‐Ping Hung Breakdown of academic impact, for papers by Laura Vincent Breakdown of academic impact, for papers by Colleen Pelser Breakdown of academic impact, for papers by Saurabh Nagar Breakdown of academic impact, for papers by Tsang-En Wang Breakdown of academic impact, for papers by Michael O’Sullivan Breakdown of academic impact, for papers by Sebastian E. Sattui Breakdown of academic impact, for papers by Floor Abbink Breakdown of academic impact, for papers by Bradley S. Stolshek
Rankless by CCL
2026